Emma Dorey is a freelance medical writer based in Brighton, UK.
Acting on the potential of action potentials: will bioelectronic medicines be the next biologics?Subscription
Bioelectronic medicine is a new approach to treating major chronic diseases that could give doctors and patients alternatives to costly mainstream medicine and may become as commonly prescribed as chemical or biological drugs. Some researchers and pharmaceutical companies are already taking this potential new class of treatments seriously and, as promising results emerge, others are expected to follow.
There are currently no effective treatments to slow or stop progressive multiple sclerosis (PMS) but recent advances in understanding the complex pathogenesis of the disease, as well as efforts to improve outcome measures, identify biomarkers and refine clinical trial design, mean progress is speeding up.
As demand for biologics increases, manufacturers are devising strategies to maximise their returns on investment and benefit patients.